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Abstract 
 
Are you aware of your inner power system?  
 
An immense power is shaping your inner world – your experience and conception of life. 
You are altering your brain chemistry, manipulating your neurochemical profile and af-
fecting your body’s physiology every day by what you do and don’t eat, what you think, 
and how and where you spend your time. Through your daily behavior and the environ-
ments in which you live, you create and shape your biochemical profile. This in turn is 
reflected in your emotions, energy, thoughts, actions, and psychological condition that 
either bring out your peak performance or that block your optimal functioning or even 
can cause sickness. 
The unbalanced homeostasis of serotonin in the body is often attributed to anxiety, de-
pression, panic attacks, insomnia, obesity, fibromyalgia, eating disorders, chronic pain, 
migraines, and alcohol abuse.  
My thesis “Serotonieric system - SNP`s and epigenetic markers - in the control of appe-
tite and satiety” describe not only a very complex subject in itself but also how it affects 
and interacts with a huge number of inner systems and pathways. 
The thesis is structured in 5 chapters:  
The first two chapters provide an overview over the most recent and significant research 
and contain important definitions and information. 
The first chapter is concerned with the genetic and epigenetic markers which are asso-
ciated with obesity and how genetic and epigenetic “talk” to each other. 
The second chapter reviews our scenery of investigation: the serotonic system: how is it  
influenced in regard to weight gain or loss. Here, not only the single receptors are close-
ly observed but also other possible factors that potentially have an impact on appetite or 
satiety. 
The third and forth chapters contain the practical part of the thesis. They provide the 
rationale and procedures of my argumentation. Consequently, the third chapter dis-
cusses the methodology of meta-analysis, its potential, complexity and limitation. The 
forth chapter is the meta-analysis of the HTR2C polymorphism (-759 C/T) to obesity 
itself. The result of the analysis can be summarized in the realization that the genetic 
variation alone only has a borderline significance to obesity. Therefore other possibilities 
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must be considered in further research, for instance a special selection of different pol-
ymorphisms or, most plausibly, the effect of epigenetic markers and environmental trig-
gers that influence us during our entire life. 
For that reason the fifth chapter is entirely dedicated to epigenetic and again, very short-
ly, genetic markers at the serotonic receptors and environmental exposure, introducing 
also personal life style choices that influence our eating behavior.  
Epigenetic research - still at its very early stage - opens a vast and exciting new dimen-
sion. A vast amount of scientific research is required to begin harnessing its staggering 
potential.       
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 Introduction: “It`s complicated” – the relationship status 
of the genetics and the epigenetics of obesity 
1.  Introduction 
 
Overweight and obesity has clearly become a major clinical and public health burden 
worldwide. In our society which is sometimes shallow and mainly focused on external 
appearance, overweight and obesity are met with personal and social criticism. But it is 
the higher risk of type-2-diabetes (T2D), cardiovascular disease, cancer and mortality 
[Flegal KM et al., 2007; Pischon T et al., 2008] correlated with the obese phenotype that 
is the main problem and center of acute research. Despite all efforts, prevailing under-
taken measures to prevent obesity such as exercise, diet, education, drug therapy and 
surgery are failing. 
To control obesity and improve prevention and therapy, we have to study and appre-
hend its pathway and mechanisms.  
In this paper I focus on the identification of genetic variations influencing obesity and 
recent evidence that could connect epigenetic events with obesity.  
Until today, more than 40 genetic variants have been identified as being connected with 
obesity and fat distribution. However, since these findings do not completely elucidate 
the heritability of obesity, other forms of variation, for example epigenetic marks, must 
be considered.  
2. Genetic variations and obesity 
 
Until 2006 the main concepts used to identify common variants shaping the obese phe-
notype were association studies within ‘candidate’ genes using case–control samples or 
parent–offspring trios or hypothesis-free genome-wide linkage mapping in families with 
multiple obese subjects. These approaches suffered from being underpowered because 
reasonable susceptibility models, as linkage are best placed to track down variants with 
high penetrance. Selecting credible candidates, the candidate-gene association ap-
proach have historically been compromised. Selection was usually founded on hypothe-
ses about biological mechanisms putatively associated with obesity pathogenesis, how-
ever, as the mechanism of much of the genome is poorly understood, it remains almost 
impossible to make well-founded decisions. In addition, the candidate-gene studies 
were far too often executed in sample sets too small to achieve confident identification 
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of variants which are now understood to be realistic in regard to their range of effect 
sizes. 
Accordingly, over the last two decades, efforts in detecting and replicating genetic vari-
ants predisposing individuals to normal forms of obesity were largely described by lim-
ited success and slow progress. This is in acute contrast to the effective gene identifica-
tion in syndromic and monogenic forms of obesity [Rankinen T, et al., 2006]. The “Hu-
man Obesity Gene Map” provides a brilliant overview of this: it contains 11 single gene 
mutations, 50 loci related to Mendelian syndromes, which are listed as relevant for hu-
man obesity, 127 candidate genes and 244 knockout or transgenic animal models, of 
which slightly fewer than 20% are repeated by 5 or more studies [Rankinen T, et al., 
2006].  A total of 253 quantitative trait loci (QTL), for diverse obesity-related pheno-
types, have been announced from 61 genomewide linkage scans and of these, only 
∼20% are assisted by more than one study [Rankinen T, et al., 2006]. 
In the past three years it has become possible to conduct hypothesis-free genom wide 
association (=GWA) testing in samples of effective size to generate persuasive associa-
tion outcomes. The dawn of the GWA studies was the result of three elements.  
1. Human genome sequence: enabled cataloguing genome-sequence variation  
2. International HapMap Consortium (http://www.hapmap.org) [A haplotype map of 
the human genome. Nature 2005]: it  taught us that, in non-African-descent popu-
lations, extensive correlations (linkage disequilibrium, LD) between neighboring 
single nucleotide polymorphisms (SNPs) constrain the number of independent 
genetic tests required to survey the genome, such that ∼80% of all common var-
iation can be sampled using ∼500 000 carefully selected SNPs [Barrett JC et 
al.,2006; Pe’er I et al. 2006].  
3. Novel genotyping methods: challenges of massively parallel SNP-typing at high 
accuracy and low cost [Fan JB et al., 2006].  
The undeniable success in identifying  loci for common forms of obesity (as defined by 
anthropometric measures: BMI, WC and/or WHR) with the GWA approach is shown in 
table 1: 15 ‘high-density’ GWAs  have yielded over 50 loci associated with obesity. 
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Table 1: Overview of GWA scans or meta-analysis for different obese phenotypes 
Reference Study name (if 
any) 
Number of 
samples in 
discovery co-
hort 
Ancestry of 
discovery 
cohort 
Phenotype 
Frayling et al. WTCCC 1924 Europeans BMI – quanti-
tative analysis 
Scuteri et al. Sardinia 4741 Europeans BMI – waist 
circumference 
(WC) quantita-
tive analysis 
Loos et al.  16 876 Northern Eu-
ropean 
BMI – quanti-
tative analysis 
Chambers et 
al. 
LOLIPOP 2684 Indian Asians Insulin re-
sistance and 
related quanti-
tative pheno-
types 
Willer et al. The GIANT 
consortium 
32 387 Europeans BMI – quanti-
tative analysis 
Thorleifsson et 
al. 
DeCODE 37 347 Europeans + 
African Ameri-
cans 
BMI – quanti-
tative analysis 
Meyre et al.  1380 and 1416 
age-matched 
normal-weight 
control 
Europeans Early onset 
and morbid 
adult obesity 
Cotsapas et al.  775 cases and 
3197 un-
ascertained 
controls 
Europeans Extreme obesi-
ty/BMI 
Scherag et al.  453 extremely 
obese young-
cases and 435 
healthy lean 
controls 
Europeans Extreme obesi-
ty/BMI 
Lindgren et al. The GIANT 
consortium 
38 580 Europeans WC and 
waist:hip-ratio 
(WHR)                 
– quantitative 
analysis 
Heard-Costa 
et al. 
The CHARGE 
consortium 
31 373 Europeans WC – quantita-
tive analysis 
Speliotes et al.  123 865 European BMI – quanti-
tative analysis 
Cho et al. KARE 8842 Asian BMI, WHR – 
quantitative 
analysis 
Heid et al. MAGIC 77 167 European WHR – quanti-
tative analysis 
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The most common known gene associated to obesity is perhaps the FTO [Frayling TM 
et al. 2007], which was identified during a GWA of T2D [Zeggini E et al., 2007]. ∼1% of 
BMI heritability is explained by the association of the FTO region and obesity. This 
means, that an adult homozygote carrier of the risk allele, has a 2–3 kg higher weight 
compared to non-risk allele [Frayling TM et al. 2007]. It is very interesting, that FTO is 
shown to influence the fat mass and was suggested to encode a 2-oxoglutarate-
dependent nucleic acid demethylase, which is related to the regulation of food intake 
[Gerken T et al., 2007]. Also, it was the decreased lipolytic effect in adipocytes reported 
[Wahlen K et al., 2008]. The precise role of the FTO locus in obesity needs further ex-
amination, because it is still unclear whether FTO or the adjacent FTM gene is respon-
sible for the effect. With reports of the discovery of FTO [Frayling TM et al. 2007; Dina C 
et al.,2007; Scuteri A et al.,2007] and the first, robust dichotomous trait associations 
[Genome-wide association study of 14,000 cases of seven common diseases and 3,000 
shared controls. Nature 2007], came the realization that the effect sizes detected would 
be smaller than anticipated and that successful analysis would need larger sample sizes 
than previously thought. This realization brought up large-scale international collabora-
tion and meta-analyses of existing data. A strong connection was found between the 
SNPs located 188 kilobases (kb) downstream from the melanocortin 4 receptor gene 
(MC4R) and BMI through the first collaboration in obesity research (Tables 1 [Loos RJ  
et al.,2008]). In individuals of Indian Asian or European ancestry it was, in parallel found 
to be associated with WC (Table 1 [Chambers JC et al., 2008]). The risk variant has 
subsequently been linked to increased fat intake and energy [Qi L et al., 2008] and the 
higher BMI reported in children is consistent with early development of obesity caused 
byMC4R mutations [Farooqi IS et al., 2003]. Larger GWA meta-analysis, through the 
Genetic Investigation of Anthropometric Trait (GIANT) Consortia and deCODE (Table 1) 
followed and informed of 8 novel obesity loci, as well as supporting the MC4R and FTO 
associations [Willer CJ et al., 2009].Some of the likely causal genes in the associated 
regions are known to act or are highly expressed in the central nervous system (CNS), 
suggesting, as in rare monogenic forms of obesity, the role of CNS pathways in predis-
position to overall obesity [Thorleifsson G et al.,2009]. Other forms of obesity (early on-
set, extreme obesity and/or morbid adult obesity) were examined in a few smaller 
GWAs [Meyre D et al.,2009; Cotsapas C et al., 2009; Scherag A et al.2010] and con-
firmed FTO, MC4R and TMEM18 BMI-associations. Also these studies reported four 
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novel associations. Cotsapas et al. [Cotsapas C et al., 2009] observed nominal evi-
dence of association for 7 of the 13 loci previously identified to influence BMI [Willer CJ 
et al., 2009; Thorleifsson G et al.,2009; Meyre D et al.,2009]. The more severe forms of 
obesity represent the extreme, of the phenotypic spectrum rather than a distinct condi-
tion, this suggests that variants influencing BMI might be responsible, although, this 
needs further confirmation in appropriately powered studies. 
A large-scale meta-analysis of 249 769 individuals supported recently 14 of these al-
ready identified obesity susceptibility loci and reported 18 novel loci associated with 
overall adiposity and BMI [Speliotes EK et al., 2010].Though the higher power of this 
study, new signals with smaller effect sizes and  lower minor allele frequencies, com-
pared to previously detected variants, were found. Further insights into the underlying 
biological mechanisms and pathways of overall obesity and weight regulation will be 
needed for the effective treatment and management of these traits but these results 
suggest that genome-wide association studies are only the first step in the identification 
of the causal variants that play a role [Speliotes EK et al., 2010]. 
 
 
 
 
 
 
 
 
3. Epigenetics and obesity 
 
 The superficial definition of epigenetics is the study of heritable mutations which affect 
gene function without changing the DNA sequence [Bird A. 2007]. The notion of epige-
netic transmission is contentious and the maintenance of their marks through genera-
tions is poorly understood [Chong S et al., 2007]. Epigenetic tacks are specific for every 
tissue and include DNA methylation and histone modifications which mediate biological 
15 
 
processes such as imprinting. As many imprinted genes are regulators of gene expres-
sion controlling growth or growth factors, imprinting disorders often feature obesity as 
one of their clinical characteristics. 
The expression of alleles according to their maternal or paternal origin is called genomic 
imprinting [Reik W et al., 1998]. It establishes a balance between the expression of the 
parental alleles influencing growth [Butler MG, 2009], resulting in counteracting growth 
effects of paternal and maternal genomes [Haig D, 1991]. In addition to growth, imprint-
ed genes are also linked to differentiation, viability, development and metabolic func-
tions [Smith FM et al., 2006].  
There are two main clusters of genomic imprinting known in humans until today:  
1. at region 11p15 containing several imprinted genes including IGF2, INS, 
KCNQ10T1 (LIT1) (paternally expressed) and H19, KCNQ1, CDKN1C, PHLDA2, 
KVLQT1 (maternally expressed) [Lee MP et al., 1999].  
2. at 15q11–q12 a cluster of at least 7 imprinted genes, including;MKRN3, 
MAGEL2, NDN, SNURF–SNRPN (paternally expressed) and UBE3A, ATP10A 
(maternally expressed) [Schweizer J et al., 1999].  
Numerous genetic events, like translocation, inversion, duplication, paternal disomy 
and hyper/hypo-methylation can occur due to failures in imprinting which result in 
obesity by altering expression of growth and cellular differentiation factors. For in-
stance; the Prader–Willi syndrome (PWS) emerges by paternal deletion or uniparen-
tal disomy at 15q11–q13. It is a syndrome characterized by severe and sometimes 
life threatening form of obesity with an early onset caused by hyperphagia on basis 
of a dysfunction in the satiety centre [Shapira NA et al.2005]. In Albright hereditary 
osteodystrophy (AHO) a moderate obesity is to be found, due to disruption of im-
printing at the GNAS gene (20q13.11 [Butler MG, 2009]. 
 
3. 1.   Mediators of genomic imprinting 
3. 1. 1. DNA methylation 
 
DNA methylation plays an important regulatory role in eukaryotic genomes. Alterations 
in methylation can affect transcription and phenotypic variation [Murrell A et al., 2004], 
but the source of variation in DNA methylation itself remains poorly understood. Sub-
stantial evidence of inter-individual variation in DNA methylation exists with age [Rakyan 
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VK et al., 2010, Teschendorff AE et al., 2010], tissue [Eckhardt F et al., 2006; Gibbs JR 
et al. 2010], and species [Enard W et al.,2004]. In mammals, DNA methylation is medi-
ated by DNA methyltransferases (DNMTs) that are responsible for de novo methylation 
and maintenance of methylation patterns during replication. Genes involved in the syn-
thesis of methylation and in DNA demethylation can also affect methylation variation. 
For example, mutations in DNMT3L [El-Maarri O et al., 2009] and MTHFR [Friso S et 
al., 2005] associate with global DNA hypo-methylation in human blood. These changes 
occur at a genome-wide level and are distinct from genetic variants that impact DNA 
methylation variability in targeted genomic regions, for example, genetic polymorphisms 
associated with differential methylation in the H19/IGF2 locus [Heijmans BT et al., 
2007].  
3. 1. 2.  Histone modifications 
 
Histone modification occure throughout the entire sequence, the unstructured N-termini 
of the histones are particulary highly modified. These modifications include acetylation, 
methylation, phosphorylation, ubiquitation and sumoylation. 
The histone acetylation is most studied form of modification. For example, acetylation of 
the K14 and K9 lysines of the tail of histone H3 by histone acetyltransferase enzymes 
(HATs) is generally correlated with competence. 
Different histone modifications are likely to function in different ways; acetylation at one 
position is likely to function differently than acetylation at another position. Also, multiple 
modifications may occur at the same time, and these modifications may work together 
to change the behavior of the nucleosome. The idea that multiple dynamic modifications 
regulate gene transcription in a systematic and reproducible way is called the histone 
code.  
Also a feature of histone modifications is that it is both tissue specific and can vary with 
age (and developmental stage). Therefore, in order to place findings in an appropriate 
context, it is of major importance that evaluation of epigenetic factors be carried out on 
suitable tissues extracted at specified times [Feinberg AP, 2008; Feinberg AP, 2010]. 
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4. Challenges 
 
4. 1. Identifying novel loci 
 
The combined effect of the loci explains only 2–3% of the inherited contribution to obesi-
ty risk. So despite the successes in susceptibility loci identification for obesity through 
the first wave of GWAs there is still a lot of work to be done. 
 
4. 2. Collaborative studies to for larger GWA meta-analysis 
 
The previously identified variants will elucidate, using the conditional analysis, whether 
some of the already identified loci contain more than one independent association with 
obesity, which would be a source of unexplored variation contributing to the missing 
heritability. Also, the next wave of GWA meta-analysis for obesity related traits incorpo-
rating >100 000 samples is finalized by the GIANT consortium. This increase in sample 
size should guaranty sufficient power to permit identification of common variants with 
even smaller effect sizes than hereto.  
 
4. 3. Copy number variations 
 
The first examples of copy number variants (CNVs) associated to obesity have been 
recently identified [Plagemann A et al., 2009] by two amendatory approaches.  CNVs 
are hard to detect due to technical constrains. For example, the SNPs linked with obesi-
ty at the NEGR1 locus are in strong linkage disequilibrium (LD) with a nearby CNV 
[Willer CJ et al., 2009]. Recently by examining SNP genotype arrays that are applying 
novel CNV detecting algorithms and are enriched in CNV information, they reported on 
chromosome 16p11.2  was an associated with obesity [Walters RG et al., 2010; Bo-
chukova EG et al.,2010]. Further approaches in larger sample sets should give a better 
understanding of total CNVs contribution to overall variation in obesity susceptibility. 
 
4. 4.  Correlation of genetic and epigenetic information 
 
Genetic and epigenetic factors are not only co-existing but intimately intertlaced, as epi-
genetic marks and DNA modifications are the direct consequence of sequence-specific 
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interactions between DNA and proteins [Ptashne M et al., 2010]. The finalization of the 
human epigenome project will enlighten our understanding of the genetic and epigenet-
ics underlying cellular homeostasis and the combination of this knowledge with the 
known environmental risks to obesity must be used so that it may eventually be applied 
and manipulated to reduce the risk for obesity. 
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Serotonin system in the coordination of 
food intake and body weight  
 
1. Introduction 
 
Serotonin (5-hydroxytryptamine; 5-HT) a biogenic amine is synthesized both in the en-
teric nervous system and the central nervous system (CNS). In the CNS, serotonin acts 
as a neurotransmitter and is released throughout most of the neuraxis. It is perhaps 
most commonly linked with the regulation of mood and anxiety, brain serotonin also co-
ordinates numerous automatic, cognitive, and other functions to maintain homeostasis 
and ensure survival and reproduction. 
 
2. Manipulation of endogenous serotonin and their 
effects on appetite 
 
As we all know from many other research areas a lot of information can be gathered 
from the manipulation of perfect, harmonic systems and in this case we take a look at 
the endogenous serotonin synthesis, bioavailability, and metabolism. The manipulation 
provides important evidence for the role of endogenous serotonin in coordinating food 
intake and body weight. Together, these data illustrate the complex relationship be-
tween the level of brain serotonin signaling and food intake — when brain serotonin sig-
naling is augmented, food intake is reduced, and vice versa.  
Numerous genetic models of serotonin receptor deficiency have been generated as well 
as pharmacological targeting of serotonin receptors have been reported.  
 
2. 1. Serotonin syntheses 
 
P-chlorophenylalanine (PCPA) is an inhibitor of tryptophan hydroxylase activity and 
therefore inhibits serotonin synthesis. Intracerebroventricular (ICV) PCPA attendance in 
adult rats, specifically targeting brain serotonin synthesis, concludes in marked weight 
gain and hyperphagia for the duration of serotonin degradation [Breisch ST et al., 1976]. 
Though, serotonin is essential for normal development, and therefore tryptophan hy-
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droxylase knockout mice show growth retardation and physiological dysfunction [Aleni-
na N et al., 2009; Savelieva KV et al., 2008; Yadav VK et al., 2009]. 
 
2. 2.  Serotonin bioavailability 
 
The application of drugs can manipulate the bioavailability of endogenous serotonin 
which affect serotonin release or serotonin reuptake through the serotonin transporter.  
D-fenfluramine, which panders serotonin outlet from the intracellular compartment into 
the synapse through the serotonin transporter [Crespi D et al., 1997] and disables sero-
tonin reuptake, produces hypophagia [Guy-Grand B, 1995; Halford JC et al., 2007].  
Actually, D-fenfluramine was to a large extent prescribed to lose weight before its with-
drawal due to adverse effects [Guy-Grand B, 1995]. Serotonin reuptake inhibitors, such 
as fluoxetine, sibutramine, and sertraline elevate extracellular serotonin levels and re-
duce appetite [Heal DJ et al., 1998; Heisler LK et al., 1997, 1999; Simansky KJ and 
Vaidya AH, 1990].  
 
2. 3. Serotonin metabolism 
 
The metabolism of serotonin can be inhibited with MAO-A inhibitors which are widely 
known as antidepressant drugs prescribed for the treatment of depression and not for 
appetite. These compounds increase extracellular serotonin levels and reduce food in-
take [Feldman JM, 1988]. 
 
 
2. 4. Serotonin receptors 
 
The serotonin receptors are divided into 7 families on the bases of on evolutionary line-
age, intracellular effectors and sequence homology, labeled as 5-HT1R to 5-HT7R 
[Nichols DE and Nichols CD, 2008]. Although some receptor families consist only of one 
single member (5-HT4R, 5-HT6R and 5-HT7R), the others contain several members: 5-
HT1R includes 1A, 1B (also known as 1Dβ in humans), 1D (also known as 1Dα in hu-
mans), 1E and 1F subtypes; 5-HT2R includes 2A (formerly 5-HT2R), 2B, and 2C (for-
merly 1C); 5-HT3R includes 3A-E; 5-HT5R includes 5A and 5B. 
Recent refined genetic studies now indicate that a primary mechanism through which 
serotonin influences appetite and body weight is via serotonin 2C receptor (5-HT2CR) 
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and serotonin 1B receptor (5-HT1BR). Therefore we now take a closer look at the dif-
ferent receptors and the complex system around serotonin. 
2. 4. 1.    5-HT1R family 
 
The inhibitory 5-HT1Rs allow feedback inhibition of serotonin neurons by serotonin. The 
5-HT1AR subtype is located both postsynaptically and on the cell soma, whereas the 5-
HT1BR is to a large extent expressed on terminals, but is also postsynaptically ex-
pressed. Application of 5-HT1AR agonists to dorsal and median raphe slices reduce 
serotonin release [Hopwood SE and Stamford JA, 2001], while the use of a 5-HT1BR 
agonist to the hippocampus, a target of 5-HT innervation, diminishes serotonin release 
[Hjorth S and Tao R, 1991]. In addition 5-HT1BRs are expressed on non-serotonergic 
terminals bocking the release of other neurotransmitters and neuropeptides [Barnes NM 
and Sharp T, 1999]. 
No changes in body weight or food intake were discovered in the initial observations of 
four different linages of 5-HT1AR knockout mice [Heisler LK et al., 1998; Parks CL et 
al., 1998; Ramboz S et al., 1998]. In 2008, a more recent research on one of the lines is 
inconsistent; one group showed no alterations in homecage feeding and body weight 
[Bechtholt AJ et al., 2008] whereas another found that the same line developed reduced 
food intake and fat pad mass [Yadav VK et al., 2009]. Locomotor activity was discoverd 
to be normal in the latter report. 5-HT1BR knockout mice displayed increased lengh and 
body weight, but not obesity (Bouwknecht et al., 2001). In behavioural satiety sequence 
analysis, 5-HT1BR knockout mice presented higher exploratory activity compared to 
wildtypes, but food intake was the same at all stages [Lee MD et al., 2004]. 
Also in a study examining the effect on appetite with the pharmacological targeting of 
the serotonin receptor, 5-HT1BR knockout mice showed attenuation of the anorectic 
response to D-fenfluramine [Lee MD et al., 2004; Lucas JJ et al., 1998]. However, 5-
HT1BR knockout mice are resistant to the anorectic effects of 5-HT2CR agonists, too, 
an outcome that is not replicated by pretreatment with 5-HT1BR antagonists in wildtype 
mice [Clifton PG et al., 2003]. This supposes that an adaptive down regulation in 5-
HT2CR activity or expression might emerge in the 5-HT1BR knockout mouse. In con-
sensus with the complex relationship between serotonin signaling and intake of food, 
systemic treatment with 5-HT1AR agonists, which would reduce serotonin release 
through autoreceptor inhibition, specifically bring to light hyperphagia, without influenc-
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ing grooming, drinking, rearing, or locomotion [Dourish CT et al., 1985] and 5-HT1AR 
antagonists diminishes palatable food intake [Moreau JL et al., 1992]. Completely dif-
ferent than 5-HT1AR agonists behaves 5-HT1BR agonists, which produce hypophagia 
and is diminished by 5-HT1BR antagonist treatment [Halford JC and Blundell JE, 1996; 
Lee MD and Simansky KJ, 1997]. These effects are probably due to heteroreceptor ac-
tion on non-serotonin neurons. Indeed, potently and selectively reduced food intake can 
be attained by a discrete infusion of a 5-HT1BR agonist into the parabrachial nucleus of 
the pons, a serotonin target site [Lee MD et al., 1998]. 5-HT1BR agonism safes the 
structure of the behavioral satiety sequence, advancing the onset of resting [Halford JC 
and Blundell JE, 1996]. This study also noticed reduced rearing behavior following 5-
HT1BR agonism, which supports the higher exploratory behavior shown in 5-HT1BR-
deficient mice described previously. 
 
2. 4. 2.   5-HT2R family 
 
5-HT2CR knockout mice exhibited lifelong hyperphagia, with higher meal duration and 
frequency, and develop late-onset obesity [Nonogaki K et al., 1998; Tecott LH et al., 
1995]. 5-HT2CR knockout mice also display a delayed behavioral satiety sequence with 
an intensified incidence of feeding and delayed onset of resting behavior [Vickers SP et 
al., 1999]. In addition to these findings the 5-HT2CR knockout mice also exhibited an 
increased locomotor activity in the homecage [Nonogaki K et al., 2003; Xu Y et al., 
2008].  
The 5-HT2CR is the only serotonin receptor for which genetic deficiency results in obe-
sity and hyperphagia, which is suspected to plays an important role in the serotonergic 
coordination of food intake and body weight. 5-HT2CR knockout mice are in addition 
untouched by the anorectic effects of D-fenfluramine and mCPP [Tecott LH et al., 1995; 
Vickers SP et al., 1999]. The extent of the energy balance phenotype displayed by the 
5-HT2CR knockout mouse is exactly the other way around by selective re-expression of 
the 5-HT2CRs exclusively in pro-opiomelanocortin (POMC) neurons [Xu Y et al., 2008]. 
No changes in food intake or bodyweight have been observed in 5-HT2AR or 5-HT2BR 
knockout mice [Nebigil CG et al., 2000; Weisstaub NV et al., 2006]. Be that as it may, a 
recent report suggests that selective bockage of 5-HT2BRs exclusively in POMC neu-
rons decreases food intake and fat pad mass, but did not change locomotor activity 
[Yadav VK et al., 2009]. 
28 
 
The significance of the 5-HT2CR in controlling food intake is supported by pharmaco-
logical studies as well. 5-HT2CR agonists reduce food intake in rodents, and these ef-
fects can be reversed by 5-HT2CR antagonists [Kennett GA and Curzon G, 1988; 
Kitchener SJ and Dourish CT, 1994; Martin RJ et al., 1998; Schreiber R and De Vry J, 
2002]. The D-fenfluramine metabolite norfenfluramine is a full 5-HT2CR agonist [Curzon 
G et al., 1997], and D-fenfluramine hypophagia is diminished by 5-HT2CR antagonists 
[Vickers SP et al., 2001]. Corresponding to the 5-HT2CR knockout phenotype, pharma-
cological blockade of 5-HT2CRs reinforces food intake [Bonhaus DW et al., 1997]. 5-
HT2CR agonism advances satiety in a manner consistent with a food preload [Kitchener 
SJ and Dourish CT, 1994]. In agreement with the hyperactivity of 5-HT2CR knockout 
mice, 5-HT2CR antagonism increases locomotor activity, while 5-HT2CR agonists di-
minish locomotor activity [Fletcher PJ et al., 2009; Martin JR et al., 1998]. Although 5-
HT2AR agonists are linked to hypophagia, they also cause stereotypys [Fox MA et al., 
2009], supposing that their effects may not be to food intake in general. 
2. 4. 3.  5-HT3R family 
 
For 5-HT3AR knockout mice there has been no food intake phenotype observed 
[Bhatnagar S et al., 2004]. However, pharmacological studies show that 5-HT3R is as-
sociated to aspect of ingestive behavior. The general 5-HT3R antagonist ondansetron, 
when it is administered to rats into the dorsal hindbrain, increases nutrient intake [Hayes 
MR and Covasa M, 2006]. But primarily the interest in 5-HT3R antagonists is to reduce 
vomiting and nausea in relationship with chemotherapy. 
 
Table 1: Feeding and body weight phenotypes of mice with genetically altered serotonin-related genes 
Genetic target Feeding and body weight associated 
phenotypes 
References 
Htr1a−/− No changes in body weight reported in 
four different lines of 5-HT1AR null mice. 
Additional analysis of one line by 
Bechtholt et al. reported higher intake of 
sucrose solution in females (potentially 
sex-hormone related), but no alterations 
in homecage feeding or body weight. In 
contrast, in the same 5-HT1AR null line, 
Yadav et al. found a smaller food intake 
and attenuated fat pad mass. 
Bechtholt AJ et al., 
2008; Yadav VK et 
al., 2009 
Htr1b−/− Mildly increased body weight and relative 
intensified in food intake and blunted re-
Bouwknecht JA et al., 
2001; Lucas JJ et al., 
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sponses to anorectic serotonergic com-
pounds 
1998 
Htr2a−/− No changes in homecage feeding, novel-
ty suppressed feeding or body weight 
reported. 
Weisstaub NV et al., 
2006 
Htr2b−/− None reported. Nebigil CG et al., 
2000 
Htr2b/Pomc−/− Mice lacking receptor expression in 
POMC neurons only, displayed reduced 
food intake and fat pad mass. 
Yadav  VK et al., 
2009 
Htr2c−/− Hyperphagia throughout life and in-
creased body weight gain from around 12 
weeks. Attenuated responses to sero-
tonergic anorectic compounds. 
Tecott LH et al., 1995 
Htr2c/Pomc Selective re-expression of 5-HT2CR spe-
cifically on POMC neurons ameliorated 
the hyperphagic and obesity phenotype in 
5-HT2CR knockout. 
Xu Y et al., 2008 
Htr2c−/−/Lepob/ob Synergistic interaction followed by a hy-
perphagic phenotype greater than either 
mutation in isolation. Compound mutants 
decreased food intake to ob/ob levels by 
5 months. Body weight of double ob/2C 
null was comparable to ob/ob mice. 
Wade JM et al., 2008 
Htr3a−/− No observed differences in body weight 
or food intake. 
Bhatnagar S et al., 
2004 
Htr4−/− Modestly reduced weight gain in home-
cage environment, despite normal food 
intake. Diminished  restraint stress-
induced hypophagia. 
Compan V et al., 
2004; Jean et al., 
2007 
Htr5a−/− Normal body weight. No data on food in-
take reported 
Grailhe R et al., 1999 
Htr6−/− Normal chow intake and body weight. On 
high fat diet, 5-HT6R knockouts are hy-
pophagic and resistant to obesity. 
Bonasera SJ et al., 
2006 
Htr7−/− Normal body weight. No data on food in-
take reported. 
Hedlund PB et al., 
2003 
 
 
 
2. 4. 4.  5-HT4R  
 
In 5-HT4R knockout mice there have been no abnormalities in basal food intake dis-
played, but these mice exhibited diminished stress-induced hypophagia [Compan V et 
al., 2004]. A 5-HT4R agonist infused into the nucleus accumbens reduces food intake, 
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while application of a 5-HT4R antagonist, as well as intraaccumbal 5-HT4R siRNA-
mediated knockdown, produce hyperphagia [Jean A et al., 2007]. 
2. 4. 5.  5-HT5R family 
 
There have been no data on food intake reported. The 5-HT5AR knockout mice are 
characterized to exhibit completely normal body weight [Grailhe R et al., 1999].  
2. 4. 6.  5-HT6R 
 
Although 5-HT6R knockout mice display a normal intake of regular chow [Bonasera SJ 
et al., 2006], these mice are hypophagic and resistant to diet-induced obesity even if 
they are  exposed to a high fat diet [Frassetto A et al., 2008]. Likewise, 5-HT6R antago-
nists diminishes food intake [Heal DJ et al., 2008; Perez-Garcia G and Meneses A, 
2005; Woolley MI et al., 2001] and ICV administration of a 5-HT6R antisense oligonu-
cleotide reduces food intake [Woolley MI et al., 2001].  
2. 4. 7.   5-HT7R 
 
5-HT7R knockout mice display normal body weight [Hedlund PB et al., 2003] and no 
data linked to food intake in this line of mice has been found. 
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3. Other reward systems and regulation 
 
3. 1. Dopamine 
 
Stanley, Wynne, McGowan, and Bloom [Stanley S et al., 2005] have observed that the 
dopaminergic system is crucial to reward-induced feeding behavior. Mice that lack do-
pamine have fatal hypophagia.  
Terasawa and Fernandez [Terasawa E & Fernandez DL, 2001] suggest that dopamine 
affects to great extent also pubertal development through its influence on the release of 
luteinizing hormone-releasing hormone. Their recent animal studies revealed that do-
pamine levels display a particular increase right before or around the time of puberty. 
Studies of rats and nonhuman primates suggest that dopaminergic input to the prefron-
tal cortex increases during adolescence, peaking at levels higher than those seen earli-
er or later in development [Spear LP, 2000].  
 
3.2. Norepinephrine 
 
A bidirectional regulation of appetite is influenced by the noradrenergic system. Activa-
tion of α1- and β2-adrenergic receptors inhibits appetite, and norepinephrine reuptake 
inhibitors that act on these receptors (e.g., phentermine) lower the food intake.  
In contrast, the α2-adrenergic receptors activate an increased food intake [Stanley S et 
al., 2005].  
 
3. 3. Opioids 
 
An important role in the reward value of food plays the endogenous opioids, which in-
clude endorphins and enkephalins. For mice lacking enkephalin or endorphin the food 
loses its reinforcement potential [Stanley S et al., 2005]. Opiate antagonists in humans 
reduce food palatability without altering subjective hunger [Stanley S et al., 2005]. This 
means that even though opioids are not directly responsible for hunger, they affect the 
hedonistic pathways that make food consumption tempting and pleasurable.  
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3. 4. Other possible factors 
 
The following factors of biological and psychological processes are not intended to be a 
complete list of moderators, but a short glance to other systems and processes that 
could maybe influence weight and appetite. 
Increased levels of proinflammatory cytokines, proteins that regulate immunity and in-
flammation, may influence weight and appetite symptoms [Carney RM et al., 2002; Rai-
son CL et al., 2006]. In concert with leptin, proinflammatory cytokines influence the cen-
tral nervous system to reduce food intake [Dixit et al., 2004].  
In addition, research assumes a possible role for proinflammatory cytokines in the tim-
ing of pubertal development viamediational effects on leptin [Quinton ND et al., 1999; 
Sarraf P et al., 1997].  
Exogenous cytokine application, either centrally or peripherally, influences mood and 
eating behavior [Konsman JP et al., 2002; Markowitz S et al., 2008].  
Another area of research suggests an important role for early life events. Neural sys-
tems are quite plastic and easy to manipulate in early development, such that early dep-
rivation, abuse, or trauma can lead to lasting and varied impairments through epigenet-
ics, alterations in the expression of genes via DNA without changes in coding sequence 
[Holmes A et al., 2005]. Pace et al. [Pace TWW et al. 2006] showed that among a group 
of men with major depression, those with higher levels of stress in their early life time 
displayed greater inflammatory responses to psychosocial stressors as adults.  
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4. Hormones 
4. 1. Corticotropin-releasing hormone (CRH) 
 
CRH is a hormone associated to the body's stress response, indirectly stimulating the 
output of glucocorticoids. Animal studies show that an over-expression of CRH leads to 
a higher food intake and weight gain (Bornstein SR et al., 2006). The activity of CRH 
seems to change during life time and especially in adolescence. Research assumes 
that CRH cells may respond differently to acute and chronic stress in prepubertal versus 
postpubertal animals, with a larger number of CRH cells activated during the stress re-
sponse of prepubertal animals [Romeo RD & McEwen BS, 2006]. It is very interesting 
that a sex difference in cortisol response to CRH seems to display in adolescence, with 
girls showing higher cortisol levels to CRH across pubertal development and boys 
showing relatively stable cortisol responses across pubertal time [Stroud LR et al., 
2004]. CRH hypersecretion appears to mediate several depressive symptoms, including 
appetite disturbance, sleep disturbance, reduced libido, and psychomotor disruptions 
[Arborelius L et al., 1999]. 
 
4. 2. Glucocorticoids 
 
A part of the stress response are the glucocorticoids, such as cortisol, which are steroi-
dal hormones secreted by the adrenal cortex. Exogenous administration of glucocorti-
coids is generally followed by metabolic changes typical of obesity [Bornstein SR et al., 
2006].  
In addition to its role as a stress hormone and regulator of the hypothalamic-pituitary-
adrenal axis, another study observed that the treatment with D-fenfluramine elevates 
Crh mRNA levels in the paraventricular hypothalamic nucleus (PVH), and 5-HT2CR null 
mice display diminished PVH Crh mRNA [Heisler LK et al., 2007].  
Also, PVH CRH neurons are activated by systemic application of D-fenfluramine and 
serotonin receptor agonists [Bovetto S et al., 1996; Javed A et al., 1999].  
Pretreatment with an anti-CRH antibody inactivates the anorectic effect of some doses 
of centrally injected serotonin or DL-fenfluramine [Le Feuvre RA et al., 1991].  
Even though PVH CRH neurons were given direct doses of serotonin [Liposits Z et al., 
1987], the activation of CRH neurons noticed after serotonin level elevation that the 
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melanocortin system may be at least in some parts a secondary effect of activation by 
serotonin. PVH CRH neurons express melanocortin 4 receptors (MC4Rs), and are ex-
tremely fast activated by melanocortin receptor agonists [Lu XY et al., 2003]. Moreover, 
pharmacological blockade of CRH receptors diminishes the anorectic effect of a mela-
nocortin receptor agonist [Lu XY et al., 2003].  
So the conclusion we could draw from those studies is that serotonin's effects on CRH 
activity may be direct, but may also be indirect through the effects of the melanocortin 
system.  
 
4. 3. Specific gonadal hormones 
 
Gonadal hormones (for instance estradiol and testosterone) have an enormous effect 
on body composition and weight. After the first six months of life, levels of gonadal hor-
mones are low until puberty, at which time the levels are reinforced dramatically [Tera-
sawa E & Fernandez DL, 2001]. Animal studies have shown that testosterone reduces 
adiposity, or fatty tissue, whereas progestin causes elevated in body weight [Wade GN 
& Gray JM, 1979]. These typical different effects of gonadal hormones for males and 
females are responsible for some of the common sex differences in relative composition 
of body weight gained during pubertal development (with males gaining relatively more 
muscle and less fat than females). 
The sudden rise of pubertal hormones is also linked to alterations in affect and risk for 
psychopathology. The surge of gonadal hormones changes the sensitivity of neuro-
transmitter systems in ways that influence mood [Steiner M et al., 2003]. The surges of 
hormones sets the genders apart in ways that may make females more vulnerable to 
negative affect and depression. [Susman EJ et al., 1987].  
 
4. 4. Leptin 
 
Leptins a peptide hormone that was already mentioned in combination with inflammato-
ry cytokines but plays also on its own an important role in weight regulation and adiposi-
ty.  A person's total fat mass is proportional to its circulating leptin levels, and admin-
istration of leptin to animals is followed by a marked reduction in food consumption and 
weight loss [Neary NM et al., 2004]. Longitudinal research has observed that during ad-
olescence, levels of leptin elevate in females and reduce in males [Ahmed ML et al., 
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1999]. This sex difference in leptin levels during adolescence is related to the fact that 
both sexes gain weight, but girls gain proportionally more fat mass than boys [Ahmed 
ML et al., 1999]. 
Licinio and Wong [Licinio J &Wong ML, 1999] assume that leptin likely influences symp-
toms of appetite and weight dysregulation also in depression. It is in fact very interesting 
that different leptin abnormalities may be responsible for depression-related weight loss 
or weight gain. This theory is supported by Kraus et al. [Kraus T et al. 2001] who 
demonstrated that individuals suffering from depression had normal BMIs, but dimin-
ished leptin levels when compared to healthy controls. Completely different evidence 
found Gecici et al., [Gecici O et al., 2005] in their study, individuals with atypical depres-
sion (characterized by hyperphagia, weight gain, hypersomnia) had higher serum leptin 
levels than the healthy controls.  
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5. Hypothalamic controls 
5. 1. Hypothalamus 
 
Hypothalamic dysfunction is the perhaps best studied genetic cause of obesity and is 
widely known to be a control of body weight [Swaab DF, 1997]. The different parts of 
the hypothalamus regulatory center for both elevated and reduced weight and appetite, 
with lesions in the ventromedial hypothalamus leading to higher food intake and weight 
gain, and lesions in the lateral hypothalamus leading to undereating and weight loss 
[Rosenbaum M & Leibel RL, 1998]. It is due to this research that we consider the ven-
tromedial hypothalamus as a satiety center and the lateral hypothalamus as a feeding 
center.  
The hypothalamus is the center of production of orexins and oxytocin.  
5. 1. 1. Orexins 
 
Orexins (=hypocretins) are orexigenic neuropeptides and are produced by neurons in 
the lateral hypothalamus [Nambu T et al., 1999; Sakurai T et al., 1998]. Orexins is an 
important factor in the coordination of arousal with food-seeking behaviour [Saper CB, 
2000]. Dense serotonin terminals surround orexin neurons and hyperpolarize following 
to serotonin application [Muraki Y et al., 2004]. 
5. 1. 2. Oxytocin 
 
Oxytocin which is established by neurons of the PVH and supraoptic nucleus of the hy-
pocampus plays a role in uterine contractions, maternal and social bonding and lactat-
ing. Since injection of oxytocin into the dorsal motor nucleus of the vagus reduces gas-
tric motility, it is suggested that oxytocin neurons may influence food intake via projec-
tions to the dorsal vagal complex [Rogers RC and Hermann GE, 1987]. Oxytocin neu-
rons are activated, and oxytocin secretion is reinforced, by D-fenfluramine and serotonin 
receptor agonists [Jorgensen H et al., 2003; Osei-Owusu P et al., 2005; Van de Kar LD 
et al., 1995, 2001; Zhang Y et al., 2002].  
Like the already discussed CRH, the involvement of oxytocin in the serotonergic system 
of food intake may be another factor aside a lot of factors to melanocortin system acti-
vation.  
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5.2. Neuropeptide Y 
 
Neuropeptide Y (NPY) is a peptide released from the arcuate nucleus that is centrally 
involved in hunger and meal initiation [Jequier E & Tappy L, 1999]. Nutrient absorption 
results in a feedback inhibition of NPY, leading to reduced hunger. NPY exerts powerful 
effects on appetite and likely interacts with several other peptides and feedback loops 
[Jequier E & Tappy L, 1999].  
NPY is co-expressed with the melanocortin receptor antagonist agouti-related peptide 
(AgRP) [Broberger C et al., 1998; Hahn TM et al., 1998]. These neurons receive sero-
tonin inputs [Guy J et al., 1988; Heisler LK et al., 2006] and are hyperpolarized by 5-
HT1BR agonists [Heisler LK et al., 2006]. Levels of NPY, and its mRNA, are decreased 
by pharmacological serotonin reinforcement [Choi S et al., 2006; Dryden et al., 1996]. 
Additionally, feeding induced by NPY administration is diminished by D-fenfluramine 
[Bendotti C et al., 1987; Grignaschi G et al., 1995]. The blockage of orexigenic 
NPY/AgRP neurons by 5-HT1BR action, directly linked with the activation of opposing 
anorexigenic POMC neurons by 5-HT2CR action, that assumes that these receptors 
support each other's effects on at least one pathway. 
 
 
 
5. 3. Melanocortins 
 
Melanocortins are anorectic hypothalamic neuropeptides which are prominently in-
volved in control of body weight and appetite. In both rodents and humans a mutation in 
the genes encoding the endogenous melanocortin agonist precursor POMC and the 
MC4R result in heavy hyperphagia and obesity [Challis BG et al., 2004; Farooqi IS et 
al., 2000; Huszar D et al., 1997; Krude H et al., 1998; Yaswen L et al., 1999; Yeo GS et 
al., 1998]. Serotonin reinforcment with D-fenfluramine, a 5-HT2C/1BR agonist, activates 
POMC-expressing neurons in the hypothalamic arcuate nucleus, which is a subpopula-
tion that express 5-HT2CRs [Heisler LK et al., 2002; Lam DD et al., 2008].  
Also interesting is that serotonin and 5-HT1BR agonists blockes neurons expressing the 
endogenous melanocortin receptor antagonist AgRP, a subpopulation of which express 
5-HT1BRs [Heisler LK et al., 2006]. A study in 2008 demonstrated that selective 5-
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HT2CR expression only on POMC neurons is enought to normalize the hyperphagia, 
obesity, and attenuated the answer to anorectic serotonergic drugs displayed by 5-
HT2CR null mice [Xu Y et al., 2008].  
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Theory of a Meta-analysis 
 
1. Introduction 
 
It is exceptionally hard to stay on top of every subject in this fluently and fast changing 
world. In the 17 century Gottfried Wilhelm Leibniz was maybe the last universal scientist 
for whom it was possible to keep track of and know everything. 
Since that time which also marks the beginning of modern science, the production of 
scientific knowledge has grown exponentially. This can be gathered from the explosive 
increase of journals. In 1750 there were roughly ten scientific magazines. This number 
increased with great exactness ten times every 50 years till the end of twentieth century. 
For today`s scientists, which are facing more and more published investigations, it is 
hardly possible to get and keep an overview of all research works even in a clearly de-
fined subject matter. Furthermore, in some research areas there are inconsistent and 
even sometimes opposing outcomes. 
This development illustrates the increased need for a possibility to condense infor-
mation and assess scientific outcomes, which led to the development of different meth-
ods to summarize outcomes. In addition to the traditional form of review, quantitative 
results combining studies, called meta-analysis came up during the 1970ies. 
 
2. History and essence of meta-analysis 
 
The first known quantitative result combining study, which we recognize nowadays as 
meta-analysis, was undertaken by the mathematician Karl Person in 1904 [Pearson, K, 
1904]. At that time the success of the typhus vaccination was not yet proven, particular-
ly because the studies were conducted with a far too small sample size and led to differ-
ing outcomes. 
Since the 1950ies the first quantitative result integrations were used for questions con-
cerning psychology and education science by Glass. The birth, of what we now call me-
ta-analysis is dated in the mid 70ties, as Gene V. Glass introduced his method of quan-
titative result integration in a talk at the annual conference of the American Education 
Research Association [Glass, GV et al. 1981]. After that date there was an uptake in the 
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number of studies combining quantitative results of previously conducted studies and 
also in the critical methodological reflection about the meta analytic method.  
What is really the essence of a meta-analysis? When Glass introduced the notion meta-
analysis, he differentiated the method as a kind of third-analysis not a primary or sec-
ondary analysis. ”Primary analysis is the original analysis of data in a research 
study.(…) Secondary analysis is the re-analysis of data for the purpose of answering 
the original research question with better statistical techniques, or answering new ques-
tions with old data. (…) meta-analysis refers to the analysis of analysis (…) the statisti-
cal analysis of large collection of analytical results from individual studies for the pur-
pose of integrating the findings” [Glass, GV, 1976] 
 
3. Structure of meta-analysis 
 
The carrying out of meta-analysis is simple in comparison with other known investiga-
tions of empiric research, like the interviewing of people, just that a meta-analysis is a 
study were the examination results represent the objects of the investigation. The inves-
tigation objects are coded, with regard to the interviewed properties and the established 
results are assessed by a statistic method chosen by the researcher [Cooper, H & 
Hedges LV, 1994b; Cooper, H, 1984; Durlak, JA & Lipsey MW, 1991]. 
The following graph shows the prototype structure of a Meta-analysis: 
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3. 1. Concretion of the Problem 
 
Like every other examination, a meta-analysis starts with the concretization of the prob-
lem, the main research question. The formulation and the rough specification of investi-
gated variables should be clear. 
 
3. 2. Selection of relevant investigations 
 
The collection of relevant investigations is the data survey of the meta-analysis. All the 
studies need to be defined with regard to the examined variables, i.e. it must be decid-
ed, which relationship of variables in the study will be investigated, so the individual 
study is chosen for the meta-analysis. 
Also other selection criteria can be a applied, like the type of publication (journals, con-
gress speeches and working papers), the time frame of relevant investigations or the 
cultural and especially the language of the examination [Lipsey, MW & Wilson, DT, 
2001] 
Only extended research and data collection guaranties that all important works will pos-
sibly be recognized and consequently no systematic bias will appear. Today electronic 
databases are mainly used for the collection of data. To guarantee even more infor-
mation the references of the collected works can be reviewed or scientist can be con-
tacted for further information. 
 
3. 3. Coding and assessment of data 
 
The coding and calculation of the found data follow as next steps. Here the usefulness 
of the individual studies for the meta-analysis is finally checked and in particular all in-
formations which are important for the meta-analytical calculation, are coded. 
 
3. 4. Data analysis 
 
The data analysis involves two steps: first, the integration of individual results, and se-
cond the examination of the variation of the individual results in comparison. 
In principle, next to the effect strength measurement for investigation results, there are 
also the integration of the level of significance or the simple possibility of counting out 
the significant and non-significant results. 
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3. 5.Presentation and interpretation of results 
 
With the presentation and interpretation of results the methodological steps should be 
described and the results should be pointed out and be summarized. The application for 
theory and practice should be mentioned and especially the possible scientific gaps, as 
well as the further research possibilities should be discussed [Halvorsen, KT, 1994]. 
The representations of the studies with the relevant properties, as well as the results 
themselves appear mainly in the form of tables. But it is also possible and in many cas-
es helpful to use a graphic description [Light, RJ et al. 1994]. 
 
4. Problems of meta-analysis and how to avoid them 
 
The meaning and value of meta-analysis has been continually and intensively dis-
cussed in particular during the 1970ies. After the first phase of propagation, the meta-
analysis was severely criticized. This phase again was followed by a consolidation, es-
tablishment and frame setting of the method [Drinkmann, A, 1990]. 
Now what exactly under current status of methodological development pleads for the 
use of meta-analysis, and what against? 
Considering the aim of meta-analysis, which again is the combination of study results 
that address a set of related research hypotheses, the meta-analysis has the following 
clear advantages over a classical review of literature [Beelmann, A & Bliesener T, 1994; 
Drinkmann, A, 1990; Glass, GV et al. 1981; Hunter, JE & Schmidt FL, 1990; Plath, I, 
1992; Wolf, FM, 1994]: 
 
• Shows if the results are more varied than what is expected from the sample di-
versity 
• Derivation and statistical testing of overall factors/ effect size parameters in relat-
ed studies 
• Generalization to the population of studies 
• Ability to control the variation between study  
• Higher statistical power to detect an effect than in n=1 sized study sample 
• Including moderators to explain variation 
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• Dealing with information overload: the high number of articles published each 
year 
• It combines several studies and will therefore be less influenced by local findings 
than single studies will be 
• Makes it possible to show if a publication bias exists 
 
Almost every literature source concerning meta-analysis mentions the following 4 points 
as the most important critics and counter-arguments.  
Today these problems are all to a great extent discussed and these following para-
graphs should just refer to the awareness of existing problems and how I handled this in 
the conducted meta-analysis.  
 
4. 1. Uniformity problem 
 
Meta-analysis combines many study results of a researched problem. These studies 
can be very different in themselves:  the method used, the characteristics of populations 
in the analysis  considering sample size or analyzing method. Such differences create 
problems of comparability. Two ways and scientific positions exist to deal with the iden-
tification and resolution of this problem [Hunter, JE, 2001]: 
                   Integrative approach         
 
                      
            
One way is a very strict approach, which only accepts perfect replications to be meta-
analyzable. This means that only studies using the same variable relations with the 
same analyzing method are examined [Lipsey, MW & Wilson, DT, 2001]. This approach 
is mainly used in natural sciences. 
Strict 
replication 
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Another very provocatively opposing way is the claim for integration by Glass. Where 
the meta-analysis is not a mere replication study, concerned with the analysis of vari-
ances, but a combination of all studies, which have the same question in mind, and 
which the researcher considers to be essential and methodological homogeneous. The 
depiction of Smith et al.`s frequently quoted statement fits this well: “Indeed the ap-
proach does mix apples and oranges, as one necessarily would do in studying fruit.” 
 
4. 2.  Publication bias 
 
The critic of the publication bias relates to the selection mechanism in the investigation 
and publication process, where the significant results are promoted and the non-
significant are filed unpublished in a drawer. So next to the published works there is 
probably a certain grey-number of examinations [Wolf, FM, 1994]. 
One very simple possibility to examine the existence of a publication bias is the funnel-
graphs.  
Funnel plots, introduced by Light and Pillemer in 1984 [Light, RJ & Pillemer, DB, 1984] 
and discussed in detail by Egger and colleagues [Egger M et al., 1997; Sterne JAC & 
Egger M, 2001] are useful adjuncts to meta-analyses. A funnel plot is a scatter plot of 
treatment effect against a measure of study size. It is used primarily as a visual aid to 
detecting bias or systematic heterogeneity. A symmetric inverted funnel shape arises 
from a ‘well-behaved’ data set, in which publication bias is unlikely. An asymmetric fun-
nel indicates a relationship between treatment effect and study size. This suggests the 
possibility of either publication bias or a systematic difference between smaller and 
larger studies (‘small study effects’). Asymmetry can also arise from use of an inappro-
priate effect measure. Whatever the cause, an asymmetric funnel plot leads to doubts 
over the appropriateness of a simple meta-analysis and suggests that there needs to be 
investigation of possible causes. 
A variety of choices of measures of ‘study size’ is available, including total sample size, 
standard error of the treatment effect, and inverse variance of the treatment effect 
(weight). Sterne and Egger have compared these with others, and conclude that the 
standard error is to be recommended [Sterne JAC & Egger M, 2001]. When the stand-
ard error is used, straight lines may be drawn to define a region within which 95% of 
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points might lie in the absence of both heterogeneity and publication bias [Sterne JAC & 
Egger M, 2001]. 
In common with confidence interval plots, funnel plots are conventionally drawn with the 
treatment effect measure on the horizontal axis, so that study size appears on the verti-
cal axis, breaking with the general rule. Since funnel plots are principally visual aids for 
detecting asymmetry along the treatment effect axis, this makes them considerably eas-
ier to interpret. 
Of course there is also a mathematical or analytical approach to check for publication 
bias. 
4. 3. Integration of studies of different quality 
 
     = Garbage in, Garbage out 
This critical point relates to the differences concerning the methological quality of the 
studies used. The problem is mainly founded on the assumption of the relation between 
methological quality and result of a study: the higher the methological quality, the 
stronger are the results. This problem could simply be resolved by excluding studies of 
inferior quality. But the difference in study quality can also be recognized in the integra-
tion of the effect size, as a kind of weight factor. Or one refers to the study quality, as a 
moderation variable, to explain the heterogeneity of the integrated data.  
An a priori exclusion of studies with inferior quality, which is proposed for a very strict 
approach of a meta-analysis, has the down side of less information, because the totality 
of the possibly included data gets smaller.  
  
4. 4. Non-independent effects 
 
Finally, with the integration of research results, the problem of dependence of results 
(non-independent effects or multiple effect size) is to be taken into consideration. This 
last criticical point of the meta-analysis relates to the fact, that several relevant effects of 
one study, which were identified with the same investigation objects, are statistically not 
independent from each other and when interpreted these dependent effects can result 
in a distorted integration result. 
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Meta-analysis: Obesity and the HTR2C 
polymorphism (-759 C/T) 
 
1. Introduction: 
 
Serotonin (5-hydroxytryptamine, 5-HT) one of the most important neurotransmitters is  
regulating energy balance and is synthesized from the amino acid tryptophan. 5-HT is 
acting in many complex events of human physiology, from the gastrointestinal and car-
diovascular systems to centrally mediated activities such as mood, sleep, appetite, glu-
cose homeostasis, temperature, sexual behavior, learning, and memory. The actions of 
serotonin are conducted through seven families of 5-HT-receptor subtypes that have 
been studied with different intensity until now. 
In the meta-analysis I took a closer look at the 5-HT2C receptor, especially the SNP -
759C/T and its association to obesity. The results of the meta-analysis were compared 
to a large population-based cohort association study [Vimaleswaran KS et al., 2010 ] 
and another meta-analysis [De Luca V et al. 2007] which was conducted using pharma-
cological induced weight gain and not general obese subjects. 
 5-HT2C receptor couples to multiple intracellular signaling pathways, is expressed in 
the hypothalamus and paraventricular nucleus [Miller KJ et al., 2005] and its gene is 
located at the chromosome Xq24 [Stam NJ et al., 1994]. 
The site of the -759C/T polymorphism contains regulatory and putative transcription fac-
tor binding regions [Shih JC et al., 1996] that regulate levels of the receptor protein, 
which could potentially change the neuronal regulation of many physiological processes 
including appetite. The -759T allele is functional and has been associated with greater 
promoter activity than the wild-type -759C allele in Yuan X et al. [Yuan X et al., 2000], a 
study we also have included in our meta-analysis. The 5-HT2C receptor is of particular 
interest in the weight gain liability as serotonin plays an important role in the energy bal-
ance and appetite regulation centers in the central nervous system (CNS) located in a 
region where lesions result in obesity [Parkinson WL et al., 1990].  
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2. Methode 
 
2. 1. Concretion of the Problem 
 
Genetic association studies of the -759C/T (SNP rs 3813929) polymorphism in adults 
assessed for obesity was included. Investigations reporting of any ethnic origin were 
included.  
 
2. 2. Selection of relevant investigations 
 
A literature search was performed in July 2011 using the PubMed online search engine. 
This database was searched from the year 2000 using the search terms “5-HT2C” and 
“HTR2C”. Additional publications were retrieved by reviewing the references of selected 
studies. 
 
2. 3. Coding and assessment of data 
 
For each study, the following data were extracted using standard forms: author, year of 
publication, sample ethnicity, case and control sample size, allele frequency, mean age, 
sex ratio. Ethnicity was coded as Caucasian and Asian. 
 
2. 4. Data analysis 
 
I used SPSS Statistics 17.0 for the descriptive statistics, like means, summes and 
standard deviation. Then I used a Microsoft Excel sheet by Rob Herbert to calculate the 
Odds and Confidence Intervals. The method used to calculate a confidence interval for 
the difference between two proportions is the Newcombe-Wilson method without conti-
nuity correction. The confidence limits for the number needed to treat are the inverse of 
the limits for the absolute risk reduction. Confidence intervals and odds ratios are calcu-
lated using the methods described by Armitage and Berry [Armitage P and Berry G 
1994].  
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2. 5.Presentation and interpretation of results 
 
Literature search identified a total of 127 papers, of which 123 had to be excluded be-
cause of various reasons, for example: 
 
• conducted in children  
• no healthy control populations included  
• incomplete data about polymorphism  
• subjects were not obese  
•  animal study 
• Weight gain induced by pharmaceutics 
 
The remaining four studies, all association studies, described a total of 3396 partici-
pants, divided in an obese of 1301 and a control group of 1850 participants.  
This resulted in a 2662 wild typ subjects and 489 being homozygote for the -759 C/T 
SNP.  
 
Table 1:  Overview of complete numbers of participants 
 Obese Control 
N 1301 1850 
Genotyp Ho 198 291 
Genotyp Wt 1103 1559 
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Table 2: The following studies were included in the analysis and in the following comparison:  
 
The first study by Yuan et al. consisted of 589 men aged 51 ± 10 years having body 
mass index (BMI) of 25.2 ± 4.0 kg/m2 recruited from people who attended the Kumamo-
to Red Cross Health Care Centre and patients treated at the Kurume University Hospi-
tal. The subjects included 123 obese (BMI ≥ 28) and 466 non-obese (BMI < 28) men. 
The second group of participants from Iordanidou M et al. included 107 (49 males and 
58 females) classified as obese [body mass index (BMI) ≥ 30 kg/m2] and 182 (113 
males and 69 females) classified as nonobese (BMI<30 kg/m2). All patients were of 
Caucasian (Greek) ethnic origin. 
In the third study by Kring SII et al. a population of obese men (n = 726, BMI ≥ 31.0 
kg/m2) and a randomly selected normal weight group (n = 831) were re-examined at two 
surveys at mean ages 46 and 49 years (S-46, S-49). In the first survey there were 1557 
Study 
  
Year n Ancestry 
Yuan X et al. 
 
2000 589 Asian 
Iordanidou M et al. 
 
2008 289 Caucasian 
Kring SII et al. 2009 s. 46: 1557 
s.49: 485 
Caucasian  
Caucasian 
 
Bah J.et al. 2010 231 Caucasian  
 
Compaired with: 
 
   
Vimaleswaran KS et al.  
Association study in a 
large population-based 
cohort 
2010 4978 Caucasian 
 
De Luca V et al. 
Meta-analysis: 
Antipsychotic induced 
weight gain 
2007 588 European, Asian, 
Hispanic and African-
American 
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(726 obese and 831 randomly selected) participants and in the re-examination there 
were 485 (209 obese and 276 randomly selected) assessed. 
The last study by Bah J et al. comprises 231 male (normal/obese) participants from 
Sweden which were included in my analysis. 
All of the studies investigated the association of the single nucleotide polymorphisms 
(SNPs) of the HTR2C gene with obesity. For the genetic analysis Yuan X et al., Bah 
J.et al. and  Iordanidou M et al. used a slightly different polymerase chain reaction 
restriction fragment. And Kring SII et al. used a Taqman allelic discrimination. 
All the four studies taken together resulted in an odds ratio of 0,9617 ( 95% CI: 0,7903 – 
1,1703) for the effect of T variant to be associated with lower weight (Table 3).  
Table 3: Odds ratio and confidence intervalls of all four studies and participants taken toghther 
        
Relative Risk: 0,9675 CI: 0,8195 to 1,1423   
Odds ratio: 0,9617 CI: 0,7903 to 1,1703   
 
Figure 1: 
 
 
Yuan et al.         Iordanidou 
M et al. 
Kring SII et 
al.                          
Kring SII et 
al.                        
Bah J.et 
al.
 
 
          OR 
 
 
             OR 
pooled 
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The vertical forest plot of studies is assessing the effect of homozygote or T variant with 
higher weight: overall genotype effect for dichotomous outcomes (random-effects mod-
el). Odds ratio (OR)>1 in favor T effect higher weight; OR<1 against T higher weight. 
The blue line presents the pooled OR of the four studies. 
The forest plot clearly shows that the studies by Iordanidou M et al., Kring SII et al. 
and Bah J.et al. are not significant for an association with a higher weight. Also the 
pooled OR gives no indication for a signifcans. The only runaway is the study by Yuan 
et al. which associates the homocygote / T variant with a lower body weight.  
 
Table 4: Genotyped distribution in (%) for the examined SNP in obese and controls participants 
in all studies 
 
Survey Total 
sample 
size 
Obes
e  
  Contr
. 
 
 
  
   Genotyp   Genotyp  
   Wt 
n         (%) 
Ho 
n         (%) 
 Wt  
n         (%) 
Ho 
n         (%) 
Yuan X et al. 
 
589 123 117    (95,122) 6        (5,878) 466 408    (87,553) 58    (12,447) 
Iordanidou M 
et al. 
 
289 107 83      (77,570) 24      (22,430) 182 141    (77,473) 41    (22,527) 
Kring SII et 
al. 
1557 
 
485 
 
726 
 
209 
613    (84,435) 
 
175    (83,732) 
113    (15,565) 
 
34      (16,268) 
831 
 
276 
695    (83,634) 
 
237    (85,870) 
136  (16,366) 
 
39    (14,130) 
Bah J.et al. 231 136 
 
115    (84,558) 21      (15,442) 95 78      (82,105) 17    (17,895) 
 
 To assess the association of the -759 C/T polymorphism with obesity, I additionally 
worked out the distribution in % of the homozygote (T variant) obese participants and 
control participants which is in both Table 4 and Figure 2 displayed. The homozygote 
frequency in the obese group and the non obese is except for one study by Yuan X et 
al. almost identical. 
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Figure 2: Comparison of the distribution in % of the homozygote obese and controls                                 
                                                 
 
3. Discussion and Comparison  
 
The aim of the current meta-analysis was to examine the possible association of the -
759C/T polymorphism of the 5-HT2C receptor gene obesity. 
But the assessed data didn`t associate the -759C/T polymorphism of the 5-HT2C recep-
tor gene with obesity. This was verified in two ways: (a) the odds ratios of all the single 
studies and the pooled odds ratio with their confidence intervals were all except one 
single study not significant, and (b) the distribution of the T allele between obese and 
nonobese patients was observed and almost identical, also with just one runaway and 
this happened to be the same study again.  
This very same study was conducted by Yuan et al. identifying the -759C/T polymor-
phism of the 5-HT2C receptor gene and showing an association of this polymorphism 
with obesity and T2DM [Yuan X et al., 2000]. The study, which included 123 obese pa-
tients, had some noticeable weaknesses, which could explain the disagreement to all 
other studies: 
The first and most obvious is that the study population only contained only men, in the 
current meta-analyses I included men and women.  
This disagreement could be also explained by the differences of the patients included in 
each study. In the meta-analyses, both men and women of Caucasian origin and Asian 
origen were included, with completely different ages. Yuan et al. studied the -759C/T 
polymorphism only in middle-aged men (mean age of 51 years), of ethnic Japanese 
origin.  
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In this case, differences in mean age of patients and in ethnicity might explain the disa-
greement in the findings between Yuan et al.`s study and the meta-analysis. 
 
All studies show differences in the range body mass index for the obese and control 
groups:  
 
In Yuan et al.`s study participants with an BMI ≥28 were matched to the obese group all 
below to the controll group. In the study by Iordanidou M et al. the obese group started 
with a BMI >30. Kring SII et al. defined obesity as 35% overweight relative to a local 
standard and this corresponds to a BMI ≥31.0 kg/m2, which proved to be above the 99th 
percentile. Bah J.et al. on the other hand used a different definition of obesity, here the 
overweight group started with an BMI of > 25. Though all these BMI ranges are 
different, they can not explain the difference between Yuan et al.`s results and those of 
the other studies which are almost identical in their outcome, even if the BMI ranges are 
varying. 
 
For a comparison I picked another association study by Vimaleswaren KS et al. from 
2010 and to round it all up another meta-analysis by De Luca et al. form 2007. 
The article “Association between serotonin 5-HT-2C receptor gene (HTR2C) polymor-
phisms and obesity-and mental health related phenotypes in a large population-based 
cohort” by Vimaleswaren KS et al. examined six HTR2C SNPs in 4978 men and wom-
en from the European Prospective Intervention into Cancer (EPIC)-Norfolk Study. To 
confirm borderline significant associations, the remaining 16003 individuals from the 
EPIC-Study were genotyped. Of the six SNPs, only the T allele of the -759 C/T SNP 
showed borderline significant association with a higher body mass index (BMI) (0,23 
kg/m2 , 95% confidence interval (CI): 0,01-0,44,  p=0,051). As this association only 
achieved borderline significance the findings were validated in the remaining cohort. 
Here the association with the BMI remained borderline significant (0,20 kg/m2, 95% CI: 
0,04-0,44, p= 0,09). 
A very similar field of research including the role of -759C/T polymorphism in body 
weight regulation is studied in schizophrenic patients receiving atypical antipsychotic 
agents, which induced weight gain [Miller D et al., 2005; Ellingrod VL et al., 2005; 
Reynolds CP et al., 2002]. Schizophrenic patients carrying the C allele were at higher 
risk to weight gain than those carrying a T allele and this finding suggested the protec-
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tive role of the T allele for the development of weight gain during treatment with atypical 
antipsychotics. 
It has been reported that the protective role of the -759T allele may result from de-
creased neuronal expression of the receptor, although it is possible that subsequent 
compensatory changes in other systems that control feeding mediate the resistance to 
antipsychotics- induced weight gain [Hill MJ  et al., 2007]. On the other hand, there are 
several studies that have not replicated the role of the -759C/T SNP in the antipsychot-
ics-induced weight gain [Tsai SJ  et al., 2002; Basile VS  et al., 2002; Theisen FM  et 
al., 2004] and this SNP was not associated with the presence of the metabolic syn-
drome in schizophrenic patients [Mulder H  et al., 2007].  
These two opposing views are investigated in a meta-analysis by De Luca et al.: 
In the Meta-Analysis “Association of the HTR2C gene and antipsychotic induced weight 
gain: a meta-analysis” De Luca et al. investigated the association of the HTR2C gene 
and  antipsychotic induced weight gain combining all published data while restricting the 
analysis to studies investigating the 759C/T.  Also ancestry (Caucasian vs. Asian) and 
clinical factors moderated any association were investigated.  
 
Characteristics of included sample: 
Study n Ancestry 
Reynolds et al. (2002) 123 Asian 
Tsai et al. (2002) 80 Asian  
Basile et al. (2002a) 73 Caucasian, African-American 
Müller et al. (2003) 59 Caucasian, African-
American, 
Hispanic 
Theisen et al. (2004) 97 Caucasian 
Templeman et al. (2005) 73 Caucasian 
Miller et al. (2005) 41 Caucasian, African-
American, 
Hispanic 
Ellingrod et al. (2005) 42 Caucasian 
 
 
With these 8 studies they also found evidence for a slight association of -759C/T with 
weight gain and significance between studies for heterogeneity. This meta-analysis pro-
vides support for the association of HTR2C in weight gain but indicates that firmly es-
tablishing the role of pharmacogenetics in clinical psychiatry requires much larger sam-
ple sizes that have been hitherto reported. 
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After careful consideration of the assessed results from the conducted meta-analysis 
and the comparison other study in a large cohort and the second meta-analyses I sug-
gest that the common HTR2C gene variants are unlikely to play a prominent role in 
obesity in the general population. 
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Summary of epigenetic and genetic markers at the 
serotonin receptors in relation to personal traits 
and environmental triggers 
1.Introduction: 
 
Appetite could be in the simplest sense explained as a feedback system, but it is con-
trolled by a complex combination of responses in the brain.  
Hypothalamic centres has been extensively studied and been noticed to integrate in-
formation about long-term energy stores and other physiological and environmental fac-
tors to demand appropriate amounts of nutrition.  
The brainstem mediates reflex satiety responses involving the sensing of short-term 
alterations in nutritional state causing the initiation of appropriate gastrointestinal and 
motor responses.  
Serotonin is not only in the ideal position to coordinate or influence the responses of the 
neuraxis but it is also closely intertwined with many other simultaneously running pro-
cesses. A significant amount of research has been conducted to characterize the inter-
actions between serotonin and this food intake neurocircuitry.  
Another very interesting and maybe beholding a lot of elucidating information, is the ge-
netic and especially the epigenetic research in regard to serotonin. In this paper, how-
ever, I will take a step back and draw a greater picture, integrating not only the envi-
ronmental triggers, but also introducing the life-style-choises, which are linked to the 
individual character and behavior in regard to appetite.  
Here I will peripherally scratch pathological eating behavior, like bulimia nervosa, binge 
eating disorder und anorexia nervosa, which was from my point of view worth mention-
ing, because these disorders are linked not only to behavior and environmental influ-
ences, but also to epigenetic and genetic markers.     
 
2. Epigenetic markers 
 
Epigenetic models may play a promising new role of genes in appetite and especially all 
kinds of eating disorders. Epigenetic effects include alterations to the ways in which 
DNA functions within the cell. Such alterations to gene processing can change the func-
tion of gene products, for instance in serotonin receptors, transcribed from the DNA 
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without polymorphisms being present in the original gene sequence. These kinds of al-
terations are likely to be a major source of individual variability in genetically regulated 
aspects of eating and its pathology.  
Histone alterations are already set up priorities of epigenetic research and involved in 
the regulation of gene expression [Szyf M et al., 2007]. There is some evidence that 
epigenetic alterations change both memory formation and fear conditioning [Miller CA & 
Sweatt JD, 2007], which are implicated in the pathogenesis and maintenance of eating 
disorders [Lascelles KRR et al., 2003].  
Short excurse: Definition of Body dissatisfaction and eating disorders: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Body dissatisfaction 
Not only adolescent females are particularly likely to report body dissatisfaction, 
also adolescent males experience body image disturbance as well. In general the 
nature of dissatisfaction seems to differentiate by gender, with the majority of wom-
en hoping to be slimmer and men equally split between those, who want to gain 
weight and those, who want to lose weight [Furnham A et al., 2002].  
Kostanski and Gullone [Kostanski M & Gullone E, 1998] examined a nonclinical 
sample of adolescents and noticed that over 80% of females and 40% of males 
were highly unhappy with their bodies. Most females considered themselves as 
being two or more sizes too big than their ideal figure, sometimes even regardless 
of their actual body mass; on the other hand, adolescent males were divided fairly 
evenly between a desire to be larger and a desire to lose weight. Males' dissatisfac-
tion was tied to body mass distribution, such that underweight males wished to gain 
muscle mass and overweight males wanted to be smaller  and lose fat mass 
[Kostanski M & Gullone E, 1998]. Appearance has become a central evaluative 
dimension in Western cultures and has important influence on self-concept and self 
esteem [Harter S, 2002; Stice E & Bearman SK, 2001]. 
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Recent data also suggests epigenetic alterations in the reducing mRNA transcription of 
the 5-HT transporter (5-HTTT; [Philibert RA et al., 2008]), which is widely implicated in 
psychiatric disorders, like bipolar- and schizophrenic disorders, and certain behavioral 
traits of eating disorder pathology.  
Taking a closer look at bulemia nervosa there was some evidence for epigenetic effects  
found on genes important for regulating serotonergic and dopaminergic function [Friel-
ing H et al., 2008; Frieling H et al., 2009], although the functional impact needs further 
investigation.  
An additional exciting part of the epigenetic research is that it also provides space for 
environmental triggers over gene transcription and processing.  
For example, one model assumes that maternal behavior changes gene function in the 
hippocampus [Weaver ICG et al, 2006] and ultimately the hypothalamic–pituitary adren-
al (HPA) stress response of individuals into adulthood [Liu D et al., 1997].  
That leads to the justified assumption that if epigenetic effects are responsible for alter-
ing some processes of gene function in the 5-HT system, then individuals exposed or 
sensitive to epigenetic influences may be further influenced for elevated feeding and 
weight.  
Eating disorders 
Today we know a variety of different forms of eating disorders.  
Anorexia nervosa generally appears in adolescence and is characterized by a severe 
restriction of food intake that results in weight loss to the point that the person has at 
most 85% of a healthy body weight.  
Bulimia nervosa may not result in weight alterations but is characterized by unusual 
patterns of food intake that vary from periods of restriction to bingeing. Bulimia typi-
cally displays in adolescence or early adulthood and often after a period of dieting, 
which may or may not have resulted in weight loss [Kaye WH et al., 2000].  
Last but not leased binge eating disorder is marked by recurrent periods of overeat-
ing without compensatory measures, like vomiting, frequently leading to rapid chang-
es in weight and sometimes also leading to obesity.  
Even though all eating disorders are very different, they are all characterized by in-
tense body dissatisfaction and certain behavioral similarities. 
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3. 5-HT receptor  
 
 The genetic and pharmacologic dysregulation of the serotonergic system is perhaps 
one of the most studied areas of research. The effects of 5-HT manipulation on feeding 
behavior have been demonstrated in both animal and human subjects [e.g., Blundell JE, 
1986; Mancilla-Diaz JM et al., 2002; Soulairac A, 1963].  
 
3.  1. 5-HT2a receptor  
 
The 5-HT2a receptor is a postsynaptic receptor that elevates neuronal activation and is 
located in a number of cortical and prefrontal areas and particularly in the caudate nu-
cleus, hippocampus, and nucleus accumbens [Barnes NM & Sharp T, 1999; Pazos A et 
al., 1987]. In response to prolonged 5-HT exposure the 5-HT2a receptor is downregu-
lated [Sanders-Bush E, 1990].  
Genetic polymorphisms of the 5-HT2a receptor have been found to be positively linked 
with novelty seeking, assuming that lower processing 5-HT2a receptors yield a higher 
likelihood of an approach response in the context of environmental uncertainty [Heck A 
et al., 2009].  
In addition, higher density of the 5-HT2a receptor in the medial prefrontal cortex (mPFC) 
correlates with the coupling of mPFC–amygdala activation, connecting 5-HT2a func-
tionality with emotionally relevant stimuli through cortico-limbic circuits [Fisher PM et al., 
2009]. So the decreased functionality or density of  5-HT2a is likely to lead to elevated 
impulsivity or difficulty regulating affect [Frokjaer VG et al., 2008; Moresco FM et al., 
2002], for example through functional polymorphisms [Nomura M et al., 2006].  
 
 
3.  2. 5-HT1a receptor  
 
5-HT1a receptor is an inhibitory autoreceptor in most of the times found on both, the 
presynaptic and postsynaptic neuron in the hippocampus, lateral septum, cingulated 
and entorhinal cortex, amygdala and raphe nuclei [Barnes NM & Sharp T, 1999]. Elec-
trophysiologic studies confirm this inhibitory effect of 5-HT1a activation decreases cell 
firing in hippocampus [Kasamo K et al., 2001], forebrain [Ashby CR Jr. et al., 1994], and 
raphe nuclei [Haddjeri N et al 2004] neurons.  
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The inhibitory role of 5-HT1a over serotonergic transmission involves also anxiety-
related phenomena. For example, diminished 5-HT1a binding is recognized in most 
anxiety disorders [Akimova E, et al. 2009]. In that way, most models of 5-HT1a dysregu-
lations suggest a higher harm avoidance [Hansenne M & Ansseau M, 1999], although 
anxiety behaviors can occur with both under or overexpression of the receptor [Over-
street DH et al., 2003]. 
The effects of 5-HT1a neurons are also observed in the consolidation and reestablish-
ment of emotional memory which is likely to play a major role in anxiety and mood dis-
turbances [Drevets WC et al., 2007; Ogren SO et al., 2008]. 
 
4. Lifestyle Choices and Environmental triggers 
 
4. 1 Chemicals  
 
In addition to genetic and epigenetic mechanisms, environmental exposure to certain 
chemicals may add to difficulty with weight control and traits like compulsivity and im-
pulsivity.  
Several chemicals that manipulate an individual's ability to regulate and metabolize li-
pids, promote adipogenesis and rate or volume of fat deposition have been identified 
[Grun F & Blumberg B, 2009a, b]. It is believed that these chemicals like, phytoestro-
gens, synthetic estrogens, and environmental estrogens, act in metabolic processes 
early in life time and change one's ability to naturally keep a normal body weight. For 
example, even a low dose of bisphenol A (BPA) exposure, a substance found in plas-
tics, leads to reduced fetal baby weight and subsequent estrous cycle dysregulation in 
offspring of rats [Rubin BS et al, 2001]. Application of BPA also yields elevated novelty 
seeking and approach behavior in rats, via dysregulation of the estrogen system [Gi-
oiosa L et al., 2007] assuming that early dysregulation of the estrogen system may lead 
to trait-based deficits in inhibition and also alterations to basic metabolic processes. 
These chemical effects seem to be functioning through estrogenic influence over en-
zymes that regulate glycolysis [Kostanyan A & Nazaryan K, 1992], insulin sensitivity 
[Kumagai S et al., 1993], mitochondrial structure and function [Justo R et al., 2005] and 
the tricarboxylic acid cycle [Yan et al., 2004].  
Summarized, the exposure to different exogenous estrogenic agents can have a notice-
able impact on energy metabolism and homeostasis [Chen JQ et al., 2009] or impul-
78 
 
sivity, perhaps even inducing susceptibility in individuals to weight changes and so pro-
moting early attempts at dieting or also the tendency for binge eating. 
 
4. 2. Stress 
 
 Stress influences eating behavior and weight in both human and animal models. Stress 
in animals showed an elevated food consumption, particularly when the stressor is re-
lated to defeat experiences [Teskey GC et al., 1984]. A Gallup poll observed that 64% 
of Americans admitted to eat to relieve tension and negative emotion [Gallup G & Cas-
telli J, 1989]. Humans often show a poorer impulse control during periods of high stress, 
so that short-term affect regulation frequently takes over self-regulatory goals [Tice DM 
et al., 2001]. Indeed, research confirms that people are more likely to eat greater 
amounts of sweet, high-fat foods when stressed [Oliver G et al., 2000]. Especially dur-
ing adolescence, when various social, educational, and physical transitions can be 
stressful [Arnett JJ, 1999], the impact of stress on food intake maybe more sever. Self-
reported levels of social stress find their peak during adolescence and early adulthood 
[Turner RJ, et al. 1995].  
 
4. 3. Exercise and energy expenditure 
 
Exercise is an important control of body weight and composition that plays a major role 
in producing and maintaining weight loss as well as preventing weight gain [Goldberg 
JH & King AC, 2006]. Even with no caloric restriction at all, weight loss can be achieved 
by increased physical activity [Ross R et al., 2000].  
Many cross-sectional studies display that regular exercise is associated with lower rates 
of depression, neuroticism, and anxiety at almost all ages, too [Moor MHM et al., 2006].  
Some of these effects appear via mechanisms similar to those underlying antidepres-
sants: through activation of monoaminergic transmission in different brain areas [Russo-
Neustadt AA et al., 2004]. For instance, physical exercise elevates both synthesis and 
metabolism of serotonin in the hypothalamus and hippocampus [Dey S et al., 1992], 
which leads to a general well-beeing. 
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4. 4. Dieting 
 
Although dieting is generally stimulated by a desire to lose weight, it is associated not 
only with weight loss but also with weight gain. Intense dieting and weight loss efforts 
have actually been shown to make especially adolescents more vulnerable for gaining 
weight, even after controlling for initial body mass [Field AE et al., 2003; Neumark-
Sztainer D et al., 2006; Stice E et al., 1999].  
There are at least two fundamental explanations existing for this relation:  
First, dieting is considered to lead to greater metabolic efficiency, which means that the 
body requires fewer calories over time to maintain the same weight [Leibel RL et al., 
1995; Wadden TA et al., 1990]. 
Second, in the early stages of the diet the resitance is too low to sustain over time, mak-
ing overeating and weight gain increasingly likely [Polivy J & Herman CP, 2002]. 
 
 
Table 1: Effects of discussed factors 
Developmental fac-
tor 
Relation to appe-
tite 
Relation to weight 
Exercise + − 
Body dissatisfaction  +/− 
Dieting +/− +/− 
Eating disorders +/− +/− 
Stress +/− +/− 
 
 
 
5.  Concusion 
 
On the basis of extensive genetic and pharmacological evidence, serotonin plays an 
important role in the control of food intake and, consequentially, body weight. The sero-
tonin system is extremely complex in terms of anatomical projections, receptor sub-
types, and its broad functional and influential roles. Nevertheless, ongoing research 
seems only to continues to scratch the surface of brain pathways underlying the regula-
tion of food intake and body weight by brain serotonin. Much remains to be understood 
about the serotonic system and its influence in food intake control, the specific roles of 
each of the serotonin receptor subtypes involved, and the nuances of the effectors 
pathways.  
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The availability of genetic techniques and research permitting fine control of gene ex-
pression is likely to be of particular importance in the further understanding of the 
mechanism through which serotonin influences food intake. Greater knowledge about 
serotonergic mechanisms affecting food intake is likely to lead to more efficient seroto-
nin-based pharmacotherapies to aid in appetite control in obese individuals.  
Currently, there is only one serotonergic drug, the selective 5- HT2CR agonist lorcaser-
in, in late stage clinical development for the treatment of adiposity. However recent re-
search assumes that a combination therapie, targeting multiple serotonergic receptors 
or other feeding-related pathways, may be more beneficial. 
 
The closing illustration should ones again remind the reader that serotonin does not 
stand on its own, but is a “global-player” influencing and being influenced by many 
“markets”.  
 
The figure below should highlights the series of factors in which the serotonergic sys-
tems an important factor in the normal and diseased development of eating behavior.  
Genetic polymorphisms from birth can reduce the efficacy of the serotonergic system. 
After birth, specific forms of stress brought about by parenting style may further com-
promise serotonergic genes. Simultaneously, the individual is exposed to environmental 
estrogens, which maybe makes the individual more vulnerable for weight gain and 
higher levels of subcutaneous fat deposition.  
Puberty brings a rapid surge of hormones, like estrogens and testosterone. Social pres-
sures to be thin or have perfectly defined body increase and the following consequence 
of these pressures may include increased attempts at dieting, but also more severe pat-
terns can occur like bingeing, and purging. This pattern will persists until the individual is 
able to harmonize the pattern and find an own balance of eating and exercise. 
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